PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark
Click to view quick news summary (Spoiler)
New data confirms that PRF Technologies' prolonged-release ropivacaine formulation, PRF-110, matches the post-operative analgesic efficacy of approved benchmark ZYNRELEF, while demonstrating superior local tissue retention and a slower absorption rate.
Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110’s potential as a long-acting, single-administration post-operative analgesic.
PRF Technologies Ltd., a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, today announced expanded results from its previously reported preclinical study directly comparing its lead product candidate, PRF-110, to ZYNRELEF® (bupivacaine and meloxicam extended-release solution), an approved extended-release product used as a benchmark in the study.The expanded results characterize the pharmacokinetic (PK) and tissue-distribution properties of PRF-110 alongside the analgesic efficacy data previously announced.
PRF-110 is a proprietary, oil-based, viscous, clear extended-release formulation of ropivacaine designed to be deposited directly into the surgical wound bed prior to closure.The product candidate is being developed to provide prolonged local analgesia following surgery through a single administration at the surgical site, with the goal of reducing the use of opioids for post-surgical pain.The study was conducted in a validated porcine post-operative pain model, using von Frey methodology, to assess both analgesic efficacy and PK properties of the two extended-release formulations.
Key Findings
- Comparable analgesic efficacy: PRF-110 and ZYNRELEF demonstrated similar reductions in mechanical sensitivity, as measured by the von Frey test, indicating comparable pain-relief performance.
- Favorable pharmacokinetic profile: PRF-110 exhibited a slower absorption rate relative to ZYNRELEF, suggesting a more gradual release of ropivacaine at the site of administration.
- Enhanced tissue retention: PRF-110 showed increased retention in local tissue along with higher local tissue exposure (Cmax), supporting prolonged availability of the active compound at the target site.
- Sustained exposure: Both formulations demonstrated sustained systemic and local drug levels, reinforcing their potential as long-acting analgesic solutions.
About PRF-110 and PRF Technologies
PRF-110 is a proprietary, oil-based, viscous, clear extended-release solution based on the local anesthetic ropivacaine and is being developed for the post-operative pain relief market.PRF-110 is designed to be deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia.The formulation is designed to remain in place at the surgical site, spread over and adhere to the wound surface, resist rapid clearance, and provide sustained local release of ropivacaine.PRF-110 is being developed to provide prolonged post-operative pain relief following a single administration, with the goal of reducing the need for repeated dosing and potentially reducing reliance on opioids after surgery.
PRF Technologies is a company focused on the reformulation of established therapeutics, and a developer of AI-driven energy optimization technologies through its DeepSolar platform.The Company’s pharmaceutical programs leverage a proprietary extended-release drug-delivery system intended to provide prolonged post-surgical pain relief while minimizing the need for repeated dosing and reducing reliance on opioids.Through DeepSolar, PRF also delivers advanced software solutions that enable both consumers and enterprises to monitor, forecast and optimize energy consumption — particularly in solar-integrated environments.This dual business model reflects PRF’s strategic commitment to applying precision technology across high-impact sectors including healthcare and sustainable energy.
